reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Virpax Pharmaceuticals, Inc.

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$1Mstalepublic float
2024-09-25most recent failure
2025-07-21delisted or deregistered

Score over time

012202220232024202520262024-01-01 · score 12023-11-15 filed late (10-Q) · investigation2024-04-01 · score 12023-11-15 filed late (10-Q) · investigation2024-07-01 · score 12023-11-15 filed late (10-Q) · investigation2024-10-01 · score 22024-09-25 auditor change2023-11-15 filed late (10-Q) · investigation2025-01-01 · score 12024-09-25 auditor change2025-04-01 · score 12024-09-25 auditor change2025-07-01 · score 12024-09-25 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

NARRATIVE The Registrant is unable to file its Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (the “Quarterly Report”) by the prescribed due date without unreasonable effort because the Registrant requires additional information necessary for it to complete the Quarterly Report. The Registrant continues to evaluate the decision of the Chancery Court of the State of Delaware that was delivered on September 1, 2023 in the litigation filed by Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. against Anthony P. Mack and the Registrant. The Registrant intends to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 as soon as practicable

NT 10-Q, filed 2023-11-15 · investigation

What it filed

2024-09-25auditor changed or resigned SEC →

2023-11-15filed late (10-Q)investigation SEC →

NARRATIVE The Registrant is unable to file its Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (the “Quarterly Report”) by the prescribed due date without unreasonable effort because the Registrant requires additional information necessary for it to complete the Quarterly Report. The Registrant continues to evaluate the decision of the Chancery Court of the State of Delaware that was delivered on September 1, 2023 in the litigation filed by Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. against Anthony P. Mack and the Registrant. The Registrant intends to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 as soon as practicable

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com